Logo Image
Feature|Articles|September 14, 2026

Why Fragmented Contract Processes Are Slowing Pharmaceutical Operations

Author(s)Tom Cowen

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.

The pharmaceutical industry has made significant investments in digital transformation, ranging from AI-led drug discovery and clinical trial optimization to advanced analytics and real-world evidence generation. As a result, digital technologies are changing how the industry discovers, commercializes and delivers medicines.

Related to this article

View more
EMA Steps Up Push for Greater Clinical Trial Transparency
EMA Steps Up Push for Greater Clinical Trial Transparency
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Read more
How QMM Can Help the C-Suite See a $100 Million Problem Early
How QMM Can Help the C-Suite See a $100 Million Problem Early
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Read more